Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
INO

Inovio Pharmaceuticals Inc

INO

0.38USD0.00 (0.00%)Market Closed
Watchlist

Market Summary

USD0.380.00
Market Closed
0.00%

INO Stock Price

View Fullscreen

INO RSI Chart

INO Valuation

Market Cap

100.5M

Price/Earnings (Trailing)

-0.61

Price/Sales (Trailing)

15.6

EV/EBITDA

-0.51

Price/Free Cashflow

-0.74

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-1233.55%

Return on Equity

-99.44%

Return on Assets

-72.28%

Free Cashflow Yield

-134.31%

INO Fundamentals

INO Revenue

Revenue (TTM)

6.4M

Revenue Y/Y

-78.82%

Revenue Q/Q

-10.58%

INO Earnings

Earnings (TTM)

-164.5M

Earnings Y/Y

10.28%

Earnings Q/Q

4.6%

Price Action

52 Week Range

0.351.99
(Low)(High)

Last 7 days

-2.6%

Last 90 days

-15.9%

Trailing 12 Months

-79.2%

How does INO drawdown profile look like?

INO Financial Health

Current Ratio

3.91

INO Investor Care

Shares Dilution (1Y)

12.36%

Diluted EPS (TTM)

-0.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202312.3M13.7M6.4M0
20222.7M2.7M11.5M10.8M
20218.3M8.2M7.6M2.8M
20202.6M3.5M3.6M8.9M
201931.8M7.5M6.3M4.1M
201839.3M36.4M33.4M30.5M
201737.6M51.8M41.9M42.2M
201643.5M44.4M32.8M35.4M
201513.3M14.8M37.1M40.6M
201414.4M17.4M9.7M10.5M
20133.9M4.2M12.9M13.5M
20128.4M6.4M4.6M4.1M
20117.9M9.2M10.5M9.8M
20108.4M7.6M6.9M6.1M
20090009.1M

Latest Insider Trading transactions for INO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 30, 2023
sumner michael john
acquired
-
-
35,000
chief medical officer
Jun 05, 2023
zoth lota s.
sold
-3,192
0.56
-5,700
-
May 16, 2023
benito simon x
acquired
-
-
19,000
-
May 16, 2023
yarno wendy l
acquired
-
-
19,000
-
May 16, 2023
zoth lota s.
acquired
-
-
19,000
-
May 16, 2023
miller ann calby
acquired
-
-
19,000
-
May 16, 2023
shepard jay
acquired
-
-
19,000
-
May 16, 2023
weiner david b.
acquired
-
-
19,000
-
May 16, 2023
dansey roger d
acquired
-
-
19,000
-
May 13, 2023
dansey roger d
acquired
-
-
12,000
-

1–10 of 50

Which funds bought or sold INO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-29.27
-833
1,338
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
reduced
-46.45
-511,438
447,340
-%
Nov 16, 2023
Creative Planning
reduced
-19.9
-2,422
5,596
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
added
-
-10.00
7.00
-%
Nov 15, 2023
GSA CAPITAL PARTNERS LLP
new
-
116,000
116,000
0.01%
Nov 15, 2023
GTS SECURITIES LLC
new
-
5,728
5,728
-%
Nov 15, 2023
Tudor Investment Corp Et Al
reduced
-59.16
-159,209
87,922
-%
Nov 15, 2023
Virtu Financial LLC
sold off
-100
-21,000
-
-%
Nov 15, 2023
MORGAN STANLEY
reduced
-19.23
-49,837
118,349
-%
Nov 15, 2023
OLD MISSION CAPITAL LLC
sold off
-100
-47,296
-
-%

1–10 of 43

Latest Funds Activity

Are funds buying INO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INO
No. of Funds

Schedule 13G FIlings of Inovio Pharmaceuticals Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 10, 2023
state street corp
0.33%
877,447
SC 13G/A
Jul 07, 2023
blackrock inc.
2.3%
6,086,623
SC 13G/A
Feb 09, 2023
state street corp
12.61%
31,472,352
SC 13G/A
Feb 09, 2023
vanguard group inc
6.83%
17,042,500
SC 13G/A
Jan 24, 2023
blackrock inc.
9.3%
23,284,119
SC 13G/A
Apr 11, 2022
state street corp
10.49%
23,267,928
SC 13G/A
Feb 11, 2022
state street corp
6.32%
13,300,430
SC 13G/A
Feb 01, 2022
blackrock inc.
8.7%
18,244,914
SC 13G/A
Feb 11, 2021
wasatch advisors inc
-
0
SC 13G/A
Feb 11, 2021
nikko asset management americas, inc.
0%
0
SC 13G/A

Recent SEC filings of Inovio Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Nov 28, 2023
DEF 14A
DEF 14A
Nov 17, 2023
PRE 14A
PRE 14A
Nov 09, 2023
S-3
S-3
Nov 09, 2023
8-K
Current Report
Nov 09, 2023
10-Q
Quarterly Report
Nov 02, 2023
8-K
Current Report
Oct 10, 2023
8-K
Current Report

Peers (Alternatives to Inovio Pharmaceuticals Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
30.9B
-
5.25% 401813.88%
-3.6K
218.4K
- -102.45%
30.5B
10.7B
8.54% -55.34%
-8.79
2.86
-53.67% -129.46%
22.2B
1.7B
4.15% -23.37%
-43.62
12.9
79.37% 56.87%
17.9B
2.3B
11.05% -8.44%
121.62
7.74
15.05% 75.21%
12.4B
3.6B
0.84% -34.33%
29.1
3.43
8.35% -51.49%
MID-CAP
7.6B
272.9M
35.37% 34.74%
-12.51
27.78
141.38% 4.43%
5.9B
-
14.36% 263.35%
-10.02
48.33
54.84% -12.96%
3.6B
631.9M
-7.32% 48.57%
-24.01
5.65
23.54% 31.53%
3.3B
223.4M
11.28% -10.13%
-16.47
14.87
- -26.24%
2.6B
240.7M
-10.83% -25.35%
-12.82
10.93
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
11.36% -14.92%
24.59
4.38
81.69% -7.29%
656.6M
1.0B
-22.00% -67.89%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.23%
-0.61
15.6
-44.11% 50.48%
39.5M
-
376.67% 112.17%
-0.61
-
- -29.23%
23.3M
-
25.24% 3980.68%
-0.49
-
- -13.74%

Inovio Pharmaceuticals Inc News

Latest updates
Stocks Register05 Dec 202304:04 pm3 days ago
Yahoo Finance10 Nov 202308:00 am28 days ago
StockNews.com10 Nov 202308:00 am28 days ago
Stocks Register07 Nov 202308:00 am31 days ago
Seeking Alpha06 Nov 202308:00 am32 days ago
PR Newswire01 Nov 202307:00 am37 days ago
MarketWatch23 Oct 202307:00 am46 days ago
Nasdaq19 Oct 202307:00 am50 days ago
Dhaka Tribune11 Oct 202307:00 am58 days ago
Seeking Alpha09 Sep 202307:00 am3 months ago
Nasdaq07 Sep 202307:00 am3 months ago
PR Newswire29 Aug 202307:00 am3 months ago
BioWorld Online10 Aug 202307:00 am4 months ago
Yahoo Finance09 Aug 202307:00 am4 months ago

Financials for Inovio Pharmaceuticals Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-10.6%1,938,7452,168,2332,207,171124,6669,154,133857,667669,814839,115291,698928,111769,2375,580,581896,7101,067,3991,327,274279,488866,863135,6742,829,9052,502,6242,000,868
Operating Expenses-3.6%35,941,45837,267,06844,067,12156,070,82144,911,177104,921,72171,932,069106,347,45460,244,85283,474,75952,925,61234,920,01936,565,61833,448,08526,559,54230,700,54124,818,65028,336,36731,364,91732,001,78828,643,551
  S&GA Expenses-26.6%9,925,05513,523,09813,890,61013,950,94411,824,04748,456,83615,953,45814,048,63513,156,18312,666,34113,881,1948,617,45810,110,50611,071,5107,448,3548,696,5865,681,4415,850,1016,975,0295,636,1416,791,693
  R&D Expenses-34.7%15,503,03223,743,97030,176,51142,119,87733,087,13056,464,88555,978,61192,298,81947,088,66970,808,41839,044,41826,302,56126,455,11222,376,57519,111,18822,003,95519,137,20922,486,26624,389,88826,365,64721,851,858
EBITDA Margin100.0%--12.01-19.17-26.57-28.21-216-191-168-26.53-16.00-22.40-17.38-47.16-59.99-12.46-7.66-----
Interest Expenses0%313,488313,488313,488313,488313,488313,488313,488480,313476,374466,726513,0341,068,0081,984,0462,846,6412,803,7552,668,8372,428,6712,194,783656,248-156,261-
Income Taxes-----------------87,764--106,771-62,800--
Earnings Before Taxes4.5%-33,929,864-35,534,533-40,649,317-54,463,139-37,783,896-108,497,311-76,908,506-106,947,580-60,169,041-82,139,958-53,967,744-22,415,20120,931,010-128,270,709-33,135,404-38,235,146-23,536,452-29,685,847-29,351,667-32,962,205-25,015,672
EBT Margin100.0%--12.34-19.56-27.06-28.66-219-194-170-27.19-16.83-23.21-18.36-50.05-63.03-13.56-8.14-----
Net Income4.6%-33,900,000-35,534,533-40,649,317-54,463,139-37,783,896-108,497,311-79,073,719-106,947,580-60,169,041-82,139,958-54,402,131-24,338,38019,171,336-129,172,466-33,135,404-37,662,038-23,090,693-29,387,226-29,219,262-32,962,205-25,015,672
Net Income Margin100.0%--12.34-19.55-27.26-28.84-221-196-171-27.48-17.33-23.78-18.76-50.33-62.69-13.35-8.04-----
Free Cashflow100.0%--32,338,571-36,961,461-36,505,141-67,552,146-51,245,185-61,882,102-38,534,821-46,659,317-78,667,141-53,078,252-52,178,566-74,540,403-27,187,069-25,593,673-13,851,789-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-17.1%193233267349392459446496536592655540438443339144152165191131141
  Current Assets-14.0%17520323431535041640044848754258847137738227694.0099.0011113588.0094.00
    Cash Equivalents-64.3%19.0053.0028.0046.0022.0041.0059.0071.0068.0059.0084.0025117921515822.0016.0020.0021.0024.0019.00
  Net PPE-10.7%6.006.007.008.0016.0016.0017.0017.0018.0018.0011.0011.0011.0011.0012.0013.0014.0014.0015.0016.0016.00
  Goodwill-100.0%-11.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.00
Liabilities-13.7%55.0064.0067.0012612516290.0096.0082.0083.0073.0079.0011425715113911510911044.0037.00
  Current Liabilities-15.8%44.0052.0055.0097.0095.0013159.0066.0051.0052.0042.0042.0041.0038.0032.0032.0020.0024.0027.0035.0028.00
Shareholder's Equity-18.4%1381691992222672983554004545095824613241861885.0036.0056.0081.0087.00104
  Retained Earnings-2.2%-1,597-1,564-1,500-1,487-1,433-1,400-1,300-1,209-1,102-1,000-960-906-881-901-772-739-702-679-649-620-587
  Additional Paid-In Capital0.2%1,7371,7341,7281,7111,7011,6941,6421,6101,5571,5511,5421,3671,2061,088958743735732727708691
Shares Outstanding-100.0%-26425825324923521921721021020218716515612510199.0098.0097.0093.0092.00
Minority Interest-------------0.000.004.002.002.003.003.000.000.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations9.9%-29,110-32,314-36,664-36,340-67,465-50,527-61,882-37,891-46,490-78,459-52,867-51,216-74,158-27,151-25,452-13,737-27,733-23,924-32,454-17,281-24,670
  Share Based Compensation-28.7%2,0792,9183,8093,2743,2348,3367,7115,4745,6205,6469,5963,8254,1583,6624,0022,0342,0803,3553,4332,1382,351
Cashflow From Investing-110.2%-5,49353,90719,00054,00144,557-10,30421,332-6,49355,95850,306-275,115-3,71639,115-42,385-51,80810,4358,27021,588-49,3377,18314,418
Cashflow From Financing-75.8%6992,883-4246,6683,81242,93928,42247,595-4403,441160,903126,939-1,695126,523213,5139,64515,5811,29478,87714,39414,565

INO Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Revenue from collaborative arrangements and other contracts$ 388,446$ 9,154,133$ 729,359$ 10,137,602
Operating expenses:    
Research and development15,503,03233,087,13069,423,513145,530,626
General and administrative9,925,05511,824,04737,338,76376,234,341
Impairment of goodwill10,513,371010,513,3710
Total operating expenses35,941,45844,911,177117,275,647221,764,967
Loss from operations(35,553,012)(35,757,044)(116,546,288)(211,627,365)
Other income (expense):    
Interest income1,938,7451,365,7596,314,1492,893,240
Interest expense(313,488)(313,488)(940,464)(940,464)
Gain (loss) on investment in affiliated entity214,374(305,061)987,758(1,776,804)
Net unrealized gain (loss) on available-for-sale equity securities(219,337)(1,833,284)3,921,819(10,641,026)
Other income (expense), net2,854(940,778)(3,850,688)(1,097,294)
Net loss before share in net loss of Geneos(33,929,864)(37,783,896)(110,113,714)(223,189,713)
Share in net loss of Geneos000(2,165,213)
Net loss$ (33,929,864)$ (37,783,896)$ (110,113,714)$ (225,354,926)
Net loss per share    
Basic (in dollars per share)$ (0.13)$ (0.15)$ (0.42)$ (0.96)
Diluted (in dollars per share)$ (0.13)$ (0.15)$ (0.42)$ (0.96)
Weighted average number of common shares outstanding    
Basic (in shares)268,622,753249,351,023263,842,074234,634,724
Diluted (in shares)268,622,753249,351,023263,842,074234,634,724

INO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 18,804,602$ 46,329,359
Short-term investments148,668,866206,669,397
Prepaid expenses and other current assets5,114,87350,130,481
Prepaid expenses and other current assets from affiliated entities34,923375,227
Total current assets174,767,197315,242,680
Fixed assets, net5,632,5117,727,997
Investment in affiliated entity2,994,9002,007,142
Intangible assets, net02,129,861
Goodwill010,513,371
Operating lease right-of-use assets9,097,27510,228,207
Other assets605,315684,044
Total assets193,097,198348,533,302
Current liabilities:  
Accrued clinical trial expenses5,011,18510,594,073
Operating lease liability2,117,9712,803,973
Grant funding liability3,806,1612,475,031
Grant funding liability from affiliated entity21,91887,673
Convertible senior notes16,488,3290
Total current liabilities43,711,02696,868,074
Convertible senior notes016,614,840
Operating lease liability, net of current portion11,194,41312,655,586
Deferred tax liabilities32,04632,046
Total liabilities54,937,485126,170,546
Stockholders’ equity:  
Preferred stock00
Common stock269,730253,090
Additional paid-in capital1,736,602,5551,710,656,191
Accumulated deficit(1,597,961,498)(1,487,847,784)
Accumulated other comprehensive loss(751,074)(698,741)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity138,159,713222,362,756
Total liabilities and stockholders’ equity193,097,198348,533,302
Nonrelated Party  
Current assets:  
Accounts receivable01,701,726
Current liabilities:  
Accounts payable and accrued expenses15,553,74279,686,885
Related Party  
Current assets:  
Accounts receivable2,143,93310,036,490
Current liabilities:  
Accounts payable and accrued expenses$ 711,720$ 1,220,439
INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
 CEO
 WEBSITEwww.inovio.com
 EMPLOYEES135

Inovio Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Inovio Pharmaceuticals Inc? What does INO stand for in stocks?

INO is the stock ticker symbol of Inovio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inovio Pharmaceuticals Inc (INO)?

As of Thu Dec 07 2023, market cap of Inovio Pharmaceuticals Inc is 100.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INO stock?

You can check INO's fair value in chart. The fair value of Inovio Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inovio Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inovio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether INO is over valued or under valued. Whether Inovio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Inovio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INO.

What is Inovio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, INO's PE ratio (Price to Earnings) is -0.61 and Price to Sales (PS) ratio is 15.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inovio Pharmaceuticals Inc's stock?

In the past 10 years, Inovio Pharmaceuticals Inc has provided -0.358 (multiply by 100 for percentage) rate of return.